Potential application of Leishmania tarentolae as an alternative platform for antibody expression

References

• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301–316.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski La. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278.
   PubMed Web of Science ®Google Scholar
• Konthur Z, Hust M, Dübel S. Perspectives for systematic in vitro antibody generation. Gene. 2005;364:19–29.
   PubMed Web of Science ®Google Scholar
• Konthur Z, Wilde J, Lim TS. Semi-automated magnetic bead-based antibody selection from phage display libraries. In: Kontermann R, Dübel S, editors. Antibody engineering. Berlin, Heidelberg: Springer; 2010. p. 267–287.
   Google Scholar
• Ch’ng ACW, Hamidon NHB, Konthur Z, et al. Magnetic nanoparticle-based semi-automated panning for high-throughput antibody selection. In: Hust M, Lim TS, editors. Phage display. Methods in molecular biology. New York (NY): Humana Press; 2018. p. 301–319.
   Google Scholar
• Chin CF, Choong YS, Lim TS. Mass spectrometry immuno assay (MSIA™) streptavidin disposable automation research tips (DAR T’s®) antibody phage display biopanning. In: Hust M, Lim TS, editors. Phage display. Methods in molecular biology. New York (NY): Humana Press, 2018. p. 285–299.
   Google Scholar
• Elgundi Z, Reslan M, Cruz E, et al. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. 2016;122:2–19.
   PubMed Web of Science ®Google Scholar
• DeFrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology. 2006;16:833–843.
   PubMed Web of Science ®Google Scholar
• Palmberger D, Rendić D, Tauber P, et al. Insect cells for antibody production: evaluation of an efficient alternative. J Biotechnol. 2011;153:160–166.
   PubMed Web of Science ®Google Scholar
• Sommaruga S, Lombardi A, Salvade A, et al. Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells. Appl Microbiol Biotechnol. 2011;91:613–621.
   PubMed Web of Science ®Google Scholar
• Yao J, Weng Y, Dickey A, et al. Plants as factories for human pharmaceuticals: applications and challenges. IJMS. 2015;16:28549–28565.
   Google Scholar
• Yin G, Garces ED, Yang J, et al. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system. MAbs. 2012;4:217–225.
   Google Scholar
• Stuart K, Brun R, Croft S, et al. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest. 2008;118:1301–1310.
   PubMed Web of Science ®Google Scholar
• Teixeira S. Control of gene expression in Trypanosomatidae. Braz J Med Biol Res. 1998;31:1503–1516.
   PubMed Web of Science ®Google Scholar
• Bates PA. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol. 2007;37:1097–1106.
   PubMed Web of Science ®Google Scholar
• Akhoundi M, Kuhls K, Cannet A, et al. A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies. PLoS Negl Trop Dis. 2016;10:e0004349.
   PubMed Web of Science ®Google Scholar
• Wallbanks K, Maazoun R, Canning E, et al. The identity of Leishmania tarentolae Wenyon 1921. Parasitology. 1985;90:67–78.
   PubMed Web of Science ®Google Scholar
• Elwasila M. Leishmania tarentolae Wenyon, 1921 from the gecko Tarentola annularis in the Sudan. Parasitol Res. 1988;74:591–592.
   PubMed Web of Science ®Google Scholar
• Novo SP, Leles D, Bianucci R, et al. Leishmania tarentolae molecular signatures in a 300 hundred-years-old human Brazilian mummy. Parasit Vectors. 2015;8:1.
   PubMed Web of Science ®Google Scholar
• Raymond F, Boisvert S, Roy G, et al. Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res. 2012;40:1131–1147.
   PubMed Web of Science ®Google Scholar
• Breitling R, Klingner S, Callewaert N, et al. Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Expr Purif. 2002;25:209–218.
   PubMed Web of Science ®Google Scholar
• Kushnir S, Gase K, Breitling R, et al. Development of an inducible protein expression system based on the protozoan host Leishmania tarentolae. Protein Expr Purif. 2005;42:37–46.
   PubMed Web of Science ®Google Scholar
• Kovtun O, Mureev S, Jung W, et al. Leishmania cell-free protein expression system. Methods. 2011;55:58–64.
   PubMed Web of Science ®Google Scholar
• Wiese M, Ilg T, Lottspeich F, et al. Ser/Thr-rich repetitive motifs as targets for phosphoglycan modifications in Leishmania mexicana secreted acid phosphatase. EMBO J. 1995;14:1067–1074.
   PubMed Web of Science ®Google Scholar
• Jones JD. Leishmania tarentolae: an alternative approach to the production of monoclonal antibodies to treat emerging viral infections. Infect Dis Poverty. 2015;4:8.
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569.
   PubMed Web of Science ®Google Scholar
• Krakow JL, Hereld D, Bangs JD, et al. Identification of a glycolipid precursor of the Trypanosoma brucei variant surface glycoprotein. J Biol Chem. 1986;261:12147–12153.
   PubMed Web of Science ®Google Scholar
• Simpson L, Thiemann OH, Savill NJ, et al. Evolution of RNA editing in trypanosome mitochondria. Proc Natl Acad Sci U S A. 2000;97:6986–6993.
   PubMed Web of Science ®Google Scholar
• Simpson L, Douglass SM, Lake JA, et al. Comparison of the mitochondrial genomes and steady state transcriptomes of two strains of the trypanosomatid parasite, Leishmania tarentolae. PLoS Negl Trop Dis. 2015;9:e0003841.
   PubMed Web of Science ®Google Scholar
• Klatt S, Konthur Z. Secretory signal peptide modification for optimized antibody-fragment expression-secretion in Leishmania tarentolae. Microb Cell Fact. 2012;11:97.
   PubMed Web of Science ®Google Scholar
• Wong CH. Protein glycosylation: new challenges and opportunities. J Org Chem. 2005;70:4219–4225.
   PubMed Web of Science ®Google Scholar
• Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol. 2010;28:917.
   PubMed Web of Science ®Google Scholar
• Roth J, Zuber C, Park S, et al. Protein N-glycosylation, protein folding, and protein quality control. Mol Cells. 2010;30:497–506.
   PubMed Web of Science ®Google Scholar
• Ferguson MA. The structure, biosynthesis and functions of glycosylphosphatidylinositol anchors, and the contributions of trypanosome research. J Cell Sci. 1999;112:2799–2809.
   PubMed Web of Science ®Google Scholar
• Khan AH, Bayat H, Rajabibazl M, et al. Humanizing glycosylation pathways in eukaryotic expression systems. World J Microbiol Biotechnol. 2017;33:4.
   PubMed Web of Science ®Google Scholar
• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7:9–14.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. 2009;30:356–362.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs. 2012;4:413–415.
   Google Scholar
• Jefferis R. Recombinant proteins and monoclonal antibodies. In: Advances in biochemical engineering/biotechnology. Berlin, Heidelberg: Springer; 2017.
   Google Scholar
• Edelman GM, Cunningham BA, Gall WE, et al. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A. 1969;63:78–85.
   PubMed Web of Science ®Google Scholar
• Alzari P, Lascombe M, Poljak R. Three-dimensional structure of antibodies. Annu Rev Immunol. 1988;6:555–580.
   PubMed Web of Science ®Google Scholar
• Narciso JET, Uy IDC, Cabang AB, et al. Analysis of the antibody structure based on high-resolution crystallographic studies. N Biotechnol. 2011;28:435–447.
   PubMed Web of Science ®Google Scholar
• Hanson QM, Barb AW. A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry. 2015;54:2931–2942.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tian Z, Thirumalai D, et al. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. J Drug Target. 2014;22:269–278.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. FcγRs in health and disease. Curr Top Microbiol Immunol. 2011;350:105–125.
   PubMed Web of Science ®Google Scholar
• Hayes JM, Cosgrave EF, Struwe WB, et al. Glycosylation and Fc receptors. In: Daeron M, Nimmerjahn F, editors. Fc receptors. Current topics in microbiology and immunology. Cham: Springer; 2014. p. 165–199.
   Google Scholar
• Bruhns P, Jönsson F. Mouse and human FcR effector functions. Immunol Rev. 2015;268:25–51.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012;526:159–166.
   PubMed Web of Science ®Google Scholar
• Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fcγ receptor. MAbs. 2016;8:1512–1524.
   Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
   PubMed Web of Science ®Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–1334.
   PubMed Web of Science ®Google Scholar
• Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs. 2011;3:568–576.
   Google Scholar
• Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs. 2012;4:17–23.
   Google Scholar
• Wörn A, der Maur AA, Escher D, et al. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J Biol Chem. 2000;275:2795–2803.
   PubMed Web of Science ®Google Scholar
• Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005;24:501–519.
   PubMed Web of Science ®Google Scholar
• Aebi M. N-linked protein glycosylation in the ER. Biochim Biophys Acta. 2013;1833:2430–2437.
   PubMed Web of Science ®Google Scholar
• Breitling J, Aebi M. N-linked protein glycosylation in the endoplasmic reticulum. Cold Spring Harb Perspect Biol. 2013;5:a013359.
   PubMed Web of Science ®Google Scholar
• Costa AR, Rodrigues ME, Henriques M, et al. Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol. 2014;34:281–299.
   PubMed Web of Science ®Google Scholar
• Higel F, Seidl A, Sörgel F, et al. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm. 2016;100:94–100.
   PubMed Web of Science ®Google Scholar
• Spiro RG. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology. 2002;12:43R–56R.
   PubMed Web of Science ®Google Scholar
• Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104:1866–1884.
   PubMed Web of Science ®Google Scholar
• Zielinska DF, Gnad F, Wiśniewski JR, et al. Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell. 2010;141:897–907.
   PubMed Web of Science ®Google Scholar
• Krapp S, Mimura Y, Jefferis R, et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 2003;325:979–989.
   PubMed Web of Science ®Google Scholar
• Meier S, Duus J. Carbohydrate dynamics: antibody glycans wiggle and jiggle. Nat Chem Biol. 2011;7:131–132.
   PubMed Web of Science ®Google Scholar
• Dalziel M, Crispin M, Scanlan CN, et al. Emerging principles for the therapeutic exploitation of glycosylation. Science. 2014;343:1235681.
   PubMed Web of Science ®Google Scholar
• Shibata-Koyama M, Iida S, Misaka H, et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol. 2009;37:309–321.
   PubMed Web of Science ®Google Scholar
• Lin CW, Tsai MH, Li ST, et al. A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc Natl Acad Sci U S A. 2015;112:10611–10616.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Jung ST, Kang TH, et al. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol. 2012;7:1596–1602.
   PubMed Web of Science ®Google Scholar
• Lifely MR, Hale C, Boyce S, et al. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology. 1995;5:813–822.
   PubMed Web of Science ®Google Scholar
• Li H, d’Anjou M. Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol. 2009;20:678–684.
   PubMed Web of Science ®Google Scholar
• Padler-Karavani V, Yu H, Cao H, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology. 2008;18:818–830.
   PubMed Web of Science ®Google Scholar
• Macher BA, Galili U. The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta. 2008;1780:75–88.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109–1117.
   PubMed Web of Science ®Google Scholar
• Qian J, Liu T, Yang L, et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem. 2007;364:8–18.
   PubMed Web of Science ®Google Scholar
• Goh JB, Ng SK. Impact of host cell line choice on glycan profile. Crit Rev Biotechnol. 2017;38(6):1–17.
   PubMed Web of Science ®Google Scholar
• Basile G, Peticca M. Recombinant protein expression in Leishmania tarentolae. Mol Biotechnol. 2009;43:273–278.
   PubMed Web of Science ®Google Scholar
• Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol. 2006;72:211.
   PubMed Web of Science ®Google Scholar
• Sørensen HP, Mortensen KK. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact. 2005;4:1.
   PubMed Web of Science ®Google Scholar
• Naegeli A, Neupert C, Fan YY, et al. Molecular analysis of an alternative N-glycosylation machinery by functional transfer from Actinobacillus pleuropneumoniae to Escherichia coli. J Biol Chem. 2014;289:2170–2179.
   PubMed Web of Science ®Google Scholar
• Wacker M, Linton D, Hitchen PG, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 2002;298:1790–1793.
   PubMed Web of Science ®Google Scholar
• Ghaderi D, Zhang M, Hurtado-Ziola N, et al. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet. 2012;28:147–176.
   PubMed Web of Science ®Google Scholar
• Vaughn J, Goodwin R, Tompkins G, et al. The establishment of two cell lines from the insect Spodoptera frugiperda (Lepidoptera; Noctuidae). In Vitro. 1977;13:213–217.
   PubMedGoogle Scholar
• Wickham T, Davis T, Granados R, et al. Screening of insect cell lines for the production of recombinant proteins and infectious virus in the baculovirus expression system. Biotechnol Prog. 1992;8:391–396.
   PubMed Web of Science ®Google Scholar
• Davis TR, Wickham TJ, McKenna KA, et al. Comparative recombinant protein production of eight insect cell lines. In Vitro Cell Dev Biol Anim. 1993;29a:388–390.
   PubMed Web of Science ®Google Scholar
• Pennock G, Shoemaker C, Miller L. Strong and regulated expression of Escherichia coli beta-galactosidase in insect cells with a baculovirus vector. Mol Cell Biol. 1984;4:399–406.
   PubMed Web of Science ®Google Scholar
• Luckow VA, Lee S, Barry G, et al. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J Virol. 1993;67:4566–4579.
   PubMed Web of Science ®Google Scholar
• Cérutti M, Golay J. Lepidopteran cells, an alternative for the production of recombinant antibodies? MAbs. 2012;4:294–309.
   PubMed Web of Science ®Google Scholar
• Hsu TA, Takahashi N, Tsukamoto Y, et al. Differential N-glycan patterns of secreted and intracellular IgG produced in Trichoplusia ni cells. J Biol Chem. 1997;272:9062–9070.
   PubMed Web of Science ®Google Scholar
• Geisler C, Aumiller JJ, Jarvis DL. A fused lobes gene encodes the processing beta-N-acetylglucosaminidase in Sf9 cells. J Biol Chem. 2008;283:11330–11339.
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim KR, Kang DG, et al. Expression of β-1,4-galactosyltransferase and suppression of β-N-acetylglucosaminidase to aid synthesis of complex N-glycans in insect Drosophila S2 cells. J Biotechnol. 2011;153:145–152.
   PubMed Web of Science ®Google Scholar
• Hollister JR, Jarvis DL. Engineering lepidopteran insect cells for sialoglycoprotein production by genetic transformation with mammalian β1, 4-galactosyltransferase and α2, 6-sialyltransferase genes. Glycobiology. 2001;11:1–9.
   PubMed Web of Science ®Google Scholar
• Mattanovich D, Branduardi P, Dato L, et al. Recombinant protein production in yeasts. In: Lorence A, editor. Recombinant gene expression. Methods in molecular biology. Totowa (NJ): Humana Press; 2011. p. 329–358.
   Google Scholar
• Wildt S, Gerngross TU. The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol. 2005;3:119.
   PubMed Web of Science ®Google Scholar
• Chiba Y, Suzuki M, Yoshida S, et al. Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae. J Biol Chem. 1998;273:26298–26304.
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Gerngross TU. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol. 2007;18:387–392.
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Bobrowicz P, Bobrowicz B, et al. Production of complex human glycoproteins in yeast. Science. 2003;301:1244–1246.
   PubMed Web of Science ®Google Scholar
• Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol. 2004;22:1409–1414.
   PubMed Web of Science ®Google Scholar
• Li H, Sethuraman N, Stadheim TA, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol. 2006;24:210.
   PubMed Web of Science ®Google Scholar
• Jin C, Altmann F, Strasser R, et al. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology. 2007;18:235–241.
   Web of Science ®Google Scholar
• Cox KM, Sterling JD, Regan JT, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol. 2006;24:1591.
   PubMed Web of Science ®Google Scholar
• Castilho A, Strasser R, Stadlmann J, et al. In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem. 2010;285:15923–15930.
   PubMed Web of Science ®Google Scholar
• Chen Q. Glycoengineering of plants yields glycoproteins with polysialylation and other defined N-glycoforms. Proc Natl Acad Sci U S A. 2016;113:9404–9406.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Pettitt J, Scully C, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A. 2011;108:20690–20694.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chung CY, Chough S, et al. Antibody glycoengineering strategies in mammalian cells. Biotechnol Bioeng. 2018;115:1378–1393.
   PubMed Web of Science ®Google Scholar
• Ezure T, Suzuki T, Shikata M, et al. A cell-free protein synthesis system from insect cells. In: Endo Y, Takai K, Ueda T, editors. Cell-free protein production. Methods in molecular biology. Humana Press; 2010. p. 31–42.
   Google Scholar
• Sissons CH. Yeast protein synthesis. Preparation and analysis of a highly active cell-free system. Biochem J. 1974;144:131–140.
   PubMed Web of Science ®Google Scholar
• Arduengo M, Schenborn E, Hurst R. The role of cell-free rabbit reticulocyte expression systems in functional proteomics. Cell-free expression. Austin (TX): Landes Bioscience; 2007. p. 1–18.
   Google Scholar
• Brodel AK, Sonnabend A, Kubick S. Cell-free protein expression based on extracts from CHO cells. Biotechnol Bioeng. 2014;111:25–36.
   PubMed Web of Science ®Google Scholar
• Johnston WA, Alexandrov K. Production of eukaryotic cell-free lysate from Leishmania tarentolae. In: Alexandrov K, Johnston WA, editors. Cell-free protein synthesis. Methods in molecular biology. Totowa (NJ): Humana Press; 2014. p. 1–15.
   Google Scholar
• Hunter DJB, Bhumkar A, Giles N, et al. Unexpected instabilities explain batch-to-batch variability in cell-free protein expression systems. Biotechnol Bioeng. 2018;115:1904–1914.
   PubMed Web of Science ®Google Scholar
• Jørgensen ML, Friis NA, Just J, et al. Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae. Microb Cell Fact. 2014;13:9.
   PubMed Web of Science ®Google Scholar
• Lee MGS, Van der Ploeg LH. Transcription of protein-coding genes in trypanosomes by RNA polymerase I. Annu Rev Microbiol. 1997;51:463–489.
   PubMed Web of Science ®Google Scholar
• Wirtz E, Hartmann C, Clayton C. Gene expression mediated by bacteriophage T3 and 17 RNA polymerases in transgenic trypanosomes. Nucl Acids Res. 1994;22:3887–3894.
   PubMed Web of Science ®Google Scholar
• Misslitz A, Mottram JC, Overath P, et al. Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes. Mol Biochem Parasitol. 2000;107:251–261.
   PubMed Web of Science ®Google Scholar
• Kushnir S, Cirstea IC, Basiliya L, et al. Artificial linear episome-based protein expression system for protozoon Leishmania tarentolae. Mol Biochem Parasitol. 2011;176:69–79.
   PubMed Web of Science ®Google Scholar
• Beverley SM, Clayton CE. Transfection of Leishmania and Trypanosoma brucei by electroporation. In: Hyde JE, editor. Protocol in molecular parasitology. Methods in molecular biology. Humana Press; 1993. p. 333–348.
   Google Scholar
• Gazdag EM, Cirstea IC, Breitling R, et al. Purification and crystallization of human Cu/Zn superoxide dismutase recombinantly produced in the protozoan Leishmania tarentolae. Acta Crystallogr F Struct Biol Cryst Commun. 2010;66:871–877.
   PubMedGoogle Scholar
• Phan HP, Sugino M, Niimi T. The production of recombinant human laminin-332 in a Leishmania tarentolae expression system. Protein Expr Purif. 2009;68:79–84.
   PubMed Web of Science ®Google Scholar
• Klatt S, Rohe M, Alagesan K, et al. Production of glycosylated soluble amyloid precursor protein alpha (sAPPalpha) in Leishmania tarentolae. J Proteome Res. 2013;12:396–403.
   PubMed Web of Science ®Google Scholar
• Just J, Lykkemark S, Nielsen CH, et al. Pericyte modulation by a functional antibody obtained by a novel single‐cell selection strategy. Microcirculation. 2017;24:e12365.
   Web of Science ®Google Scholar
• Pereira M. A developmentally regulated neuraminidase activity in Trypanosoma cruzi. Science. 1983;219:1444–1446.
   PubMed Web of Science ®Google Scholar
• Schenkman S, Eichinger D, Pereira M, et al. Structural and functional properties of Trypanosoma trans-sialidase. Annu Rev Microbiol. 1994;48:499–523.
   PubMed Web of Science ®Google Scholar
• Grilo AL, Mantalaris A. The increasingly human and profitable monoclonal antibody market. Trends Biotechnol. 2018;37:9–16.
   PubMed Web of Science ®Google Scholar